Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study.
COVID-19
Disease modifying therapy
Multiple sclerosis
SARS-CoV-2 IgG antibody
Journal
Journal of neuroimmunology
ISSN: 1872-8421
Titre abrégé: J Neuroimmunol
Pays: Netherlands
ID NLM: 8109498
Informations de publication
Date de publication:
15 10 2021
15 10 2021
Historique:
received:
09
06
2021
revised:
29
07
2021
accepted:
13
08
2021
pubmed:
22
8
2021
medline:
22
9
2021
entrez:
21
8
2021
Statut:
ppublish
Résumé
To determine the influence of high-efficacy disease modifying therapy (DMT) on the development of IgG SARS-CoV-2 antibody response in COVID-19 convalescent people with multiple sclerosis (pwMS). Seventy-four pwMS taking high-efficacy DMTs (specifically natalizumab, fingolimod, alemtuzumab, ocrelizumab, cladribine and ublituximab) and diagnosed with COVID-19 and 44 healthy persons (HC) were enrolled. SARS-CoV2 antibodies were tested with Elecsys® Anti-SARSCoV-2 S assay. pwMS taking high-efficacy DMTs had a significantly higher chance of having negative titer of SARS-CoV2 antibodies compared to healthy controls (33 negative pwMS [44.6%] compared to one negative HC [2.3%], p < 0.001). pwMS taking B-cell depleting therapy (ocrelizumab and ublituximab) had a significantly higher chance of having negative titer of SARS-CoV2 antibodies compared to pwMS on all other DMTs (29 negative pwMS on B-cell therapy [64.4%] compared to four negative pwMS on all other DMTs [13.8%], p < 0.001). Out of other DMTs, two (33.3%) pwMS taking fingolimod and two (16.7%) pwMS taking cladribine failed to develop IgG SARS-COV-2 antibodies. B-cell depleting therapy independently predicted negative titer of IgG SARS-CoV-2 antibody (Exp[B] =0.014, 95%CI 0.002-0.110, p < 0.001). A significant proportion of convalescent COVID-19 pwMS on high-efficacy DMTs will not develop IgG SARS-CoV-2 antibodies. B-cell depleting therapies independently predict negative and low titer of IgG SARS-CoV-2 antibody.
Identifiants
pubmed: 34418815
pii: S0165-5728(21)00223-X
doi: 10.1016/j.jneuroim.2021.577696
pmc: PMC8366037
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Immunologic Factors
0
Immunosuppressive Agents
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
577696Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.
Références
JAMA Neurol. 2020 Sep 1;77(9):1079-1088
pubmed: 32589189
JAMA Neurol. 2021 Jun 1;78(6):699-708
pubmed: 33739362
Ther Adv Neurol Disord. 2021 Apr 22;14:17562864211012835
pubmed: 34035836
Mult Scler. 2021 May;27(6):864-870
pubmed: 33856242
Eur J Neurol. 2021 Oct;28(10):3384-3395
pubmed: 33340215
Nat Biotechnol. 2021 May;39(5):533-534
pubmed: 33981082
JAMA Neurol. 2021 Jul 1;78(7):880-882
pubmed: 33929488
Mult Scler Relat Disord. 2021 Jul;52:103014
pubmed: 34000684
J Neurol. 2021 Nov;268(11):3947-3960
pubmed: 34021772
Ann Neurol. 2021 Apr;89(4):780-789
pubmed: 33480077
Clin Microbiol Infect. 2021 Sep;27(9):1349.e1-1349.e6
pubmed: 33975009
Eur J Neurol. 2021 Oct;28(10):3403-3410
pubmed: 33896086
Mult Scler Relat Disord. 2020 Aug;43:102174
pubmed: 32464584